Phase 1 Randomized, Double-blind Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in Healthy African Adults
Latest Information Update: 30 Apr 2025
At a glance
- Drugs Pfs25 Pfs230 malaria vaccine MVI (Primary) ; R 21 (Primary) ; Matrix M
- Indications Falciparum malaria
- Focus Adverse reactions
- Sponsors Serum Institute of India
Most Recent Events
- 25 Apr 2025 Planned End Date changed from 30 Oct 2025 to 1 Oct 2025.
- 25 Apr 2025 Planned primary completion date changed from 30 Apr 2025 to 1 Oct 2025.
- 25 Apr 2025 Status changed from not yet recruiting to active, no longer recruiting.